Best Practice for IND Exemption Studies, IND Preparation and Maintenance

PART 1: IND Exemption Studies
PART 2: IND Preparation and Maintenance

Erin K O’Reilly, PhD, RAC
Associate Director, Regulatory Affairs

October 15, 2014
Regulatory Affairs Office

Bruce Burnett, PhD, RAC
Director

Erin O’Reilly, PhD, RAC
Associate Director

Jelena P. Berglund, PhD, RAC
Associate Director

Amanda Parrish, PhD, RAC
Associate Director

Erika Segear Johnson, PhD
Regulatory Affairs Associate

Preeti Chugha, PhD
Regulatory Affairs Associate

Audrey Perry
Administrative Assistant
How to Reach Us.

Our contact information:

– bruce.burnett@duke.edu or 668-7178
– jelena.petrovic@duke.edu or 265-7089
– amanda.b.parrish@duke.edu or 668-8772
– erin.oreilly@duke.edu or 668-4635
– preeti.chugh@dm.duke.edu or 668-8685
– erika.segearjohnson@dm.duke.edu or 668-4639
Our Website
Templates and Instructions

- Best Practices Templates/Instructions
  
  http://tinyurl.com/b759np3

Recorded Webcasts

http://tinyurl.com/8n34gr4
Outline for Part 1: IND Exemption Studies

- Definitions
- Studies Using Investigational Drugs
- Studies Using Commercially Available Drugs
- On-label Versus Off-label Use
- FDA Regulations and Guidance on IND Exemptions
- FDA Review Process
- Specific Issues
- Case Scenarios
What is a Drug?

- A Drug is anything that meets the definition of a drug per the FD&C Act (201(g)(1)).

  “. . .articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals. . .”

  “…a substance (other than food) intended to affect the structure or any function of the body”*

* Note: “…compounds administered to blunt or provoke a physiological response or to study the mechanism of action or metabolism of a drug.”
What is an Investigational Drugs?

- An article that is not approved (for marketing) in the US as a drug
- An approved drug that is not used according to the approved label (or used in a new combination of approved drugs)

Note: Practice of medicine allows a physician to use any approved drug without prior regulatory approval
What is a Clinical Investigation?

As defined by 21 CFR 312.2(b):

“...[an] experiment in which a drug is administered or dispensed to, or used involving, one or more human subjects. For the purposes [of the IND regulations], an experiment is any use of a drug [whether approved or unapproved] except for the use of a marketed drug in the course of medical practice.”
Outline for Part 1: IND Exemption Studies

- Definitions
- Studies Using Investigational Drugs
- Studies Using Commercially Available Drugs
- On-label Versus Off-label Use
- FDA Regulations and Guidance on IND Exemptions
- FDA Review Process
- Specific Issues
- Case Scenarios
Studies Using Investigational Drugs Require Investigational New Drug (IND) application

IND application is a request to the FDA for authorization to administer an investigational drug (or biologic) to humans or a marketed drug in a new indication and/or patient population.
Test Article

Not approved in US for marketing as a drug

Investigational Drug

Requires an IND
Outline for Part 1: IND Exemption Studies

- Definitions
- Studies Using Investigational Drugs
- Studies Using Commercially Available Drugs
- On-label Versus Off-label Use
- FDA Regulations and Guidance on IND Exemptions
- FDA Review Process
- Specific Issues
- Case Scenarios
What are Commercially Available Drugs?

- Articles that are approved for marketing in the US as drugs

*Note*: approval is for marketing a drug in a specific manner as defined by the drug labeling

Studies using commercially available drugs may or may not require an IND

*It depends!*

DTMI

Transforming Medicine
Test Article

Not approved in US for marketing as a drug

Investigational Drug

Requires an IND

Approved in US for marketing as a drug

Commercially Available Drug

Need an IND?
Outline for Part 1: IND Exemption Studies

- Definitions
- Studies Using Investigational Drugs
- Studies Using Commercially Available Drugs
- On-label Versus Off-label Use
- FDA Regulations and Guidance on IND Exemptions
- FDA Review Process
- Specific Issues
- Case Scenarios
On-label Versus Off-label Use

- What is drug labeling?

Drug labeling refers to all the printed material that accompanies a drug, including the label, the wrapping and the package insert.

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

http://dailymed.nlm.nih.gov/dailymed/about.cfm
On-label versus Off-label Use

**On-label Use**

Same indication, same dose, same route of administration, same patient population, same drug formulation

Studies involving the on-label use of a drug do not require an IND*

* *Note:* as long as data will not be used in a marketing application
Test Article

Not approved in US for marketing as a drug

Investigational Drug

Requires an IND

Approved in US for marketing as a drug

Commercially Available Drug

Need an IND?

On-label

IND not required*

* Assuming no marketing application planned
On-label versus Off-label Use

- Off-label Use
  - Any difference from what is approved in the label
  - Off-label use is common and allowed in the practice of medicine and often is the standard of care
Test Article

Not approved in US for marketing as a drug

Investigational Drug

Requires an IND

Approved in US for marketing as a drug

Commercially Available Drug

Need and IND?

On-label

IND not required*

Off-label

It depends!

* Assuming no marketing application planned
Outline for Part 1: IND Exemption Studies

- Definitions
- Studies Using Investigational Drugs
- Studies Using Commercially Available Drugs
- On-label Versus Off-label Use
- FDA Regulations and Guidance on IND Exemptions
- FDA Review Process
- Specific Issues
- Case Scenarios
FDA Regulations and Guidance on IND Exemptions

- 21 CFR Part 312.2(b) – IND Exemptions
- FDA Guidance Document: “IND Exemptions for Studies of Lawfully Marketed Drug or Biologic Products for the Treatment of Cancer”
  http://tinyurl.com/nqkbkd
  http://tinyurl.com/2g7z7kv
FDA Regulations and Guidance on IND Exemptions

- When is an IND not needed for studies involving marketed drugs?
  - Some studies using commercially marketed drugs
  - Some studies using *in vitro* diagnostic biological products (blood grouping serum, reagent red blood cells, anti-human globulin)
  - Studies using drugs only *in vitro* or in laboratory research animals

21 CFR Part 312.2(b)
FDA Regulations and Guidance on IND Exemptions

- First Hurdle –

21 CFR 312.2(b)(1) - Must be the “investigation of a drug product that is lawfully marketed in the United States” 21 CFR 312.2(b)(1)
Five criteria must all be met if a study can be considered exempt from requiring an IND:

1. If the study is not designed to support approval of a new indication or a change in label.
2. If the study is not intended to support a significant change in the advertising for the product.
3. If the study does not involve a route of administration, dosage level or patient population that significantly increases the risks (or decreases the acceptability of the risks) associated with the use of the drug.

4. The study is conducted in compliance with the IRB and informed consent regulations.

5. The study is conducted in compliance with regulations regarding promotion for investigational drugs.
FDA Regulations and Guidance on IND Exemptions

Evaluate risks associated with the changes in:

- Patient Population
- Route of Administration
- Dose
- Drug Combinations
- Drug Modification
V. EXAMPLES OF STUDIES

The following examples of studies are being provided to illustrate the Agency's current thinking on the types of studies that the Agency considers to be exempt from IND regulation based on a risk assessment.

A. Studies That Generally Are Exempt

As noted above, of the five criteria in § 312.2(b)(1), four are not protocol related and one is protocol related. The following are examples of general categories of studies of marketed cancer drugs that would likely be exempt from IND regulation based on protocol-related issues.

1. Single-arm, phase 2 trials using marketed drugs to treat a cancer different from that indicated in the approved labeling and using doses and schedules similar to those in
B. Studies That Generally Are Not Exempt

As noted above, of the five criteria in § 312.2(b)(1), four are not protocol related and one is protocol related. The following are examples of general categories of studies of marketed cancer drugs that would likely not be exempt from IND regulation because of protocol-related issues.

1. Studies of cytotoxic drugs are normally not exempt in patients for whom cytotoxic therapy would not be considered standard therapy and would require special justification. Any use of cytotoxic agents in nonmalignant disease (e.g., rheumatoid arthritis, multiple sclerosis) would, most likely, be considered to alter the acceptability of the risk of the agent.

2. Studies of adjuvant chemotherapy (chemotherapy given after surgery to remove cancer) are likely not exempt for the following reasons:
Route of Administration…

“For example, there could be a significant increase in risk if marketed drug for oral administration is converted to a dosage form that is to be administered by injection or intravenous, intrathecal, or inhalation route.”

http://tinyurl.com/2g7z7kv
“It is possible that a decrease in dose could also significantly increase risk. For example, administering a low dose of a pure polysaccharide vaccine to study subjects can induce hypo-immunologic or non-immunologic responses in the subjects and can also induce tolerance to the vaccine, thus making subjects at risk for the infectious disease the vaccine is intended to prevent.”

http://tinyurl.com/2g7z7kv
Drug Modifications. . .

- The exemption provision was not intended to require use of only the marketed product

- Sponsor-investigator can make low-risk modifications to the lawfully marketed drug (e.g. over-encapsulation, changes to color, scoring or size for blinding purposes)

- Consult FDA and provide detailed manufacturing information such that a determination can be made

http://tinyurl.com/2g7z7kv
Drug Combinations. . .

Remember – the use of new drug combinations not supported by literature are generally **not exempt**.

“Unless adequately described in the literature, initial studies involving new drug combinations should be performed under an IND because of the possible occurrence of synergistic toxicity.”

http://tinyurl.com/nqkbkd
Use of Placebo... 

“A clinical investigation involving the use of a placebo is exempt... If the investigation does not otherwise require submission of an IND.”

21 CFR Part 312.2(b)(5)
Test Article

Not approved in US for marketing as a drug

Investigational Drug

Requires an IND

Approved in US for marketing as a drug

Commercially Available Drug

Need an IND?

On-label

IND not required*

Off-label

It depends!

* Assuming no marketing application planned
Do you have to go to the FDA to get an IND Exemption?

YES

or

NO
According to the FDA...

“because the assessment of risks involved in a therapeutic procedure is an everyday part of the practice of medicine, the individual investigator should usually be able to determine the applicability of the exemption.”

- This statement is found in both FDA Guidance documents on IND Exemptions
IRB Submission – First Step!

- Investigator should submit their rationale for why the study is IND exempt directly to the IRB.
  - May use a checklist or a narrative statement
  - Check local IRB policies

- If IRB does not agree – then go to FDA
Other Reasons to go to FDA

- Time Constraints
- Industry partner requests FDA input before they will donate drug or release funding
- If the situation is unclear from the start
- Your local policy requires FDA input
Outline for Part 1: IND Exemption Studies

- Definitions
- Studies Using Investigational Drugs
- Studies Using Commercially Available Drugs
- On-label Versus Off-label Use
- FDA Regulations and Guidance on IND Exemptions
- FDA Review Process
- Specific Issues
- Case Scenarios
If FDA Evaluates the Study

- FDA will assess risk by focusing on:
  - Dose
  - Schedule
  - Route of Administration
  - Patient Population
  - Drug Combinations
FDA Review Process

- **Formal Process**
  
  On a 30-day review clock
  
  If not exempt... you will have an active IND

- **Informal Process**
  
  Less work ‘up front’
  
  Might get a faster response
The Formal Process

- Study may be exempt – what should the FDA submission look like?

**Cover Letter**

**IND**

IND Document *(Important in case you are NOT exempt!)*

Protocol

Consent (optional)

Forms 1571, 1572, 3674

Letters of Authorization

Reprints from the literature *(2-3 references are acceptable)*
State in the first paragraph that you believe the study may be exempt

Restate the five exemption criteria and how/why you meet them

- Focus on safety (Number 3 of exemption criteria)
Informal Process for Obtaining Exemption

- Pre-IND Consultation Contacts

http://tinyurl.com/kskl6e
Informal Process

- Call consultation contact and explain situation (we feel the study meets exemption criteria but need some guidance)
- Ask if they will consider reviewing the study
- Send cover letter, protocol synopsis and full protocol for review
- You should receive a decision within two weeks (response might be verbal or written from FDA)
Outline for Part 1: IND Exemption Studies

- Definitions
- Studies Using Investigational Drugs
- Studies Using Commercially Available Drugs
- On-label Versus Off-label Use
- FDA Regulations and Guidance on IND Exemptions
- FDA Review Process
- Specific Issues
- Case Scenarios
Specific Issues

- Endogenous Compounds
- Live Organisms
- Dietary Supplements
- Research with Noncommercial Intent
Endogenous Compounds

- Endogenous compounds (those naturally found in the body)

- Often used in challenge studies to evoke physiological response, characterize a disease or establish mechanism of action

- These studies require an IND!

*Note:* Although there is not intent to treat or mitigate disease, there is intent to affect the structure or function of the body.
A Drug is anything that meets the definition of a drug per the FD&C Act. . .

```
articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. . ."
```

```
articles intended to affect the structure or any function of the body. . ."
```

*Note:* not limited to compounds intended for a therapeutic purpose
Live Organisms

- Challenge studies with live organisms (viruses, bacteria and fungi) administered to study pathogenesis or host response require INDs

**Note:** Although there is no therapeutic purpose, there is intent to affect the structure/function of the body
Dietary Supplements are defined as products taken by mouth that are intended to supplement the diet and contain a dietary ingredient. Examples include vitamins, minerals, herbs/botanicals, amino acids, metabolites (including extracts or combinations of these things).
Dietary Supplements

Need for an IND is determined by intent. . .

Structure/Function Study = no IND Required

Examples:

- Studying the effect of calcium on bone mass
- Studying the effect of fiber on bowel regularity
Dietary Supplements

Need for an IND is determined by intent. . .

Therapeutic Studies require INDs (treat, diagnose, cure, mitigate. . . )

Examples:

- Studying the effect of calcium on osteoporosis prevention
- Studying the effect of fiber to treat diarrhea
Research with Noncommercial Intent

The IND regulations apply to investigations regardless if the intent of the study is commercial or non-commercial.
Case Scenarios
PART 2
How do You Establish and Maintain an IND?

Erin K O’Reilly, PhD, RAC
Associate Director, Regulatory Affairs

June 10th and 11th, 2014
Outline for Part 2: Preparation and Maintenance of an IND

- Definitions and Types of INDs
- Standard Paper IND Format and Content
- Forms
- Filing and FDA Review Process
- Other IND Formats
- IND Maintenance
- Case Scenarios
Definitions

- **Sponsor** is an individual, company, academic institution, or other organization that takes responsibility for and initiates a clinical investigation.

- **Investigator** is an individual who conducts a clinical trial under whose immediate direction a drug is administered or dispensed.

- **Sponsor-Investigator** is an individual who both initiates and conducts an investigation, and under whose immediate direction a drug is administered or dispensed.
Definitions: Types of INDs

- Commercial IND
  Ultimate goal is to obtain marketing approval

- Sponsor-Investigator IND
  (Investigator- Initiated IND)
  Primarily research-driven (goal is publication)
Definitions: Types of INDs

Expanded Access:

- Individual patients, including emergencies
- Moderate sized populations
- Large populations under a treatment IND/protocol
Outline for Part 2: Preparation and Maintenance of an IND

- Definitions and Types of INDs
- IND Format and Content
- Forms
- Filing and FDA Review Process
- Other IND Formats
- IND Maintenance
- Case Scenarios
IND Format & Content

1. Form 1571 (cover sheet)
2. Table of Contents
3. Introductory Statement
4. General Investigation Plan
5. Investigators Brochure
6. Protocols
7. Chemistry, Manufacturing and Control Data (CMC)
8. Pharmacology and Toxicology Data
9. Previous Human Experience
10. Additional Information

http://tinyurl.com/b759np3
It is best practice to ‘follow the script’ and maintain these standard headings.

Why??
Original INDs Received

- CDER

![Graph showing the number of INDs received by year](image)

FDA-TRACK
IND Content for Sponsor-Investigator

1. Form 1571 (cover sheet)
2. Table of Contents
3. Introductory Statement
4. General Investigation Plan
5. Investigators Brochure
6. Protocols
7. CMC
8. Pharm/Tox
9. Previous Human Experience
10. Additional Information
What Information Do I Need for Each Section?

- FDA-Approved Drug – off label
- Investigational Drug (non-FDA approved) – from company
- Investigational Drug (non-FDA approved) – you control manufacturing
- Cellular Therapy Product
IND Content

1. Form 1571 (cover sheet)
2. Table of Contents
3. Introductory Statement
4. General Investigation Plan
5. Investigators Brochure
6. Protocols
7. CMC
8. Pharm/Tox
9. Previous Human Experience
10. Additional Information

Can be referenced to drug labeling or to letters of authorization (cross reference letter).
What is a Letter of Authorization?

- This is a letter from a sponsor (company) to their IND (or IDE or DMF) stating that confidential information from their submission can be used in support of your submission.

- Thus, the FDA has “permission” to reference the named materials in support of your IND.

- Get copies of the letters to include in your submission.
Do you need a Letter of Authorization?

- For use of an investigational drug?  
  Probably

- For use of a commercially marketed drug?  
  Probably Not
IND Format & Content

1. Form 1571 (cover sheet)
2. Table of Contents
3. Introductory Statement
4. General Investigation Plan
5. Investigators Brochure
6. Protocols
7. Chemistry, Manufacturing and Control Data (CMC)
8. Pharmacology and Toxicology Data
9. Previous Human Experience
10. Additional Information
Section 6 - Protocols

- Can submit more than one
- Things that go in this section...
  - Protocol (Section 6.1)
  - Informed Consent (Section 6.2)
  - CVs for principal investigator(s) and FDA Form 1572(s) (Section 6.3)
IND Format & Content

1. Form 1571 (cover sheet)
2. Table of Contents
3. Introductory Statement
4. General Investigation Plan
5. Investigators Brochure
   5.1 Letter of Authorization
6. Protocols
   6.1 Protocol
   6.2 Informed Consent
   6.3 Investigator and Facilities Data
7. Chemistry, Manufacturing and Control Data (CMC)
8. Pharmacology and Toxicology Data
9. Previous Human Experience
10. Additional Information
Previous Human Experience

- May not be any previous human experience if drug is completely new
- May be able to refer to published literature
  - Same indication
  - Different indication
Outline for Part 2: Preparation and Maintenance of an IND

- Definitions and Types of INDs
- IND Format and Content
- Forms
- Filing and FDA Review Process
- Other IND Formats
- IND Maintenance
- Case Scenarios
FORMS

- 1571 (Section 1)
- 1572 (Section 6.3)
- 3674 (Section 1 or 10)

Make sure that you have the right version!

http://www.fda.gov/AboutFDA/ReportsManualsForms/Forms/default.htm
Key components of the FDA Form 1571

- Contractual agreement between sponsor and FDA
- Name of person responsible for conduct and progress of the study (Item 14)
- Name of person responsible for the review and evaluation of safety information on the drug (Item 15)
- Sponsor agrees to conduct investigation in accordance with all applicable regulatory requirements (Item 16)
- Must be submitted with each submission to your IND.
Key components of the FDA Form 1572

- Contractual agreement between an Investigator and the Sponsor
- Name of person responsible for conduct an investigation and their credentials (Items 1 & 2)
- Listing of the facilities and labs that are participating in the investigation (Items 3 & 4)
- Listing of the IRB responsible for reviewing/approving study (Item 5)
- Listing of additional Sub-Investigators (Item 6)
- Investigator agrees to conduct investigation in accordance with all applicable regulatory requirements (Item 9 - Commitments)
- Should submit when you have information to update
FDA Form 3674

- Requirement as of December 2007
- Form is a Certification of Compliance that all requirements of the Public Health Service Act (42 USC § 282(j)) have been met.

In other words, certification of registration at http://clinicaltrials.gov

Find Help: http://prsinfo.clinicaltrials.gov
### CERTIFICATION STATEMENT / INFORMATION

9. **CHECK ONLY ONE OF THE FOLLOWING BOXES** *(See instructions for additional information and explanation)*

- **A.** I certify that the requirements of 42 U.S.C. § 282(j), Section 402(j) of the Public Health Service Act, enacted by 121 Stat. 823, Public Law 110-85, do not apply because the application/submission which this certification accompanies does not reference any clinical trial.

- **B.** I certify that the requirements of 42 U.S.C. § 282(j), Section 402(j) of the Public Health Service Act, enacted by 121 Stat. 823, Public Law 110-85, do not apply to any clinical trial referenced in the application/submission which this certification accompanies.

- **C.** I certify that the requirements of 42 U.S.C. § 282(j), Section 402(j) of the Public Health Service Act, enacted by 121 Stat. 823, Public Law 110-85, apply to one or more of the clinical trials referenced in the application/submission which this certification accompanies and that those requirements have been met.


   NCT Number(s):  

   [Blank lines for additional NCT numbers]
Which drug trials must be registered?

“Applicable Clinical Trials”

- Interventional studies (drugs, biologics, devices)
- Phase 2 – 4 (not typical phase 1 drug – safety)
- US FDA jurisdiction (e.g., IND/IDE or US site)
- Studies initiated after September 27, 2007, or initiated on or before that date and were still ongoing as of December 26, 2007

The law also requires results reporting for a subset of these studies.

Note: ICMJE requires more broad registration than the law.
Deadline(s) for Registering Trials

- ICMJE Policy – Study must be registered prior to enrollment of first subject. In other words, if the PI wants to publish the data – you should follow this practice.

- LAW – No later than 21 days after enrollment of the first subject. This is required by US Public Law, you must do this!
IND Content for Sponsor-Investigator

1. Forms 1571 & 3674
2. Table of Contents
3. Introductory Statement
4. General Investigation Plan
5. Investigators Brochure
   5.1 Letter of Authorization and/or product labeling
6. Protocols
   6.1 Protocol
   6.2 Informed Consent
   6.3 Form 1572 & CV
7. CMC
8. Pharm/Tox
9. Previous Human Experience
10. Additional Information (Reprints)

Mainly take from protocol

‘L of A’ and/or product labeling

DTMI
Outline for Part 2: Preparation and Maintenance of an IND

- Definitions and Types of INDs
- IND Format and Content
- Forms
- Filing and FDA Review Process
- Other IND Formats
- IND Maintenance
- Case Scenarios
Filing the IND

- Cover Letter (it is a good idea to get second contact name on the cover letter)

- An original and two copies
  - Less than 3 copies may result in delays
  - Original in a grey ACCO-like report cover
  - 2 copies in different colors other than grey
  - Must be paginated uniquely throughout
Filing the IND

Where to send initial submission?

For a Drug (CDER):
U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Central Document Room
5901 Ammendale Road
Beltsville, MD 20705-1266
Attn: [Name of Div. Dir.]

For a Biologic (CBER):
U. S. Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Room
10903 New Hampshire Avenue
WO71, G112
Silver Spring, MD 20993-0002
Attn: [Name of Div. Dir.]

Who to address?
- Usually the Division Director in the Initial IND Submission
Filing the IND

★ CDER – Can request a pre-assigned application number (3 business days)
★ Email cderappnumrequest@fda.hhs.gov

Subject: Request for a Pre-Assigned `<insert Application Type>` Number

Text:
— Name of Applicant that will be on form (FDA 1571 or 356h) or transmittal letter (Master File)
— Applicant Address (street, city, state, zip code)
— Name of US Contact, Phone Number, Fax Number, Email Address
— Name of drug or Subject of Master File `<insert Established Drug Name (if applicable); or sponsor code name with short description of product, Dosage Form, Strengths if applicable>`
— Drug Trade Name (if applicable)
— Indication
— Review Division (if known)

http://tinyurl.com/pdafv3h
What happens after you submit?

- FDA to respond within 30 days
- Sponsor receives ‘acknowledgement’ letter with IND number
  - Name of ‘project manager’ (address this person in future correspondence)
  - Save this letter!
- If no issues are identified by day 30, the IND is considered to be in effect (“approved”)
  - FDA does not routinely send letter stating that IND is in effect
  - This 30th day after receipt is your ‘effective date’!!
What if there are issues with the IND?

- The FDA’s primary objective in all reviews is to ensure the safety and rights of subjects.

- Commitments in writing will often preclude a clinical hold (This would be submitted as an amendment to the IND).

- If issues cannot be resolved within this 30 day period, the FDA places the study (or IND) on “clinical hold”.

- When hold is lifted – verify the ‘effective date’.
Outline for Part 2: Preparation and Maintenance of an IND

- Definitions and Types of INDs
- IND Format and Content
- Forms
- Filing and FDA Review Process
- Other IND Formats
- IND Maintenance
- Case Scenarios
IND Format & Content - CTD

1. Module 1 – Administrative
2. Module 2 – Summary
3. Module 3 – Quality
4. Module 4 – Safety
5. Module 5 – Efficacy

1. Form 1571 (cover sheet)
2. Table of Contents
3. Introductory Statement
4. General Investigation Plan
5. Investigators Brochure
6. Protocols
7. CMC
8. Pharm/Tox
9. Previous Human Experience
10. Additional Information

Enables electronic submissions to FDA
IND Format & Content – Expanded Access

- Single-patient IND (30 day review, AR)
  - Cover letter and 1571
  - Patient History
  - Proposed Treatment Plan
  - CMC & Pharm/Tox
  - Informed Consent
  - Investigator Qualification Info (1572/CV)

- Emergency IND (EIND)
  - Checklist and eligibility tool available on FDA website

- Intermediate Size Population

- Treatment IND
  - Note: Protocol to Existing IND feasible

http://tinyurl.com/muzd2c
http://tinyurl.com/k2tskkh
http://tinyurl.com/mau5hco
Outline for Part 2: Preparation and Maintenance of an IND

- Definitions and Types of INDs
- IND Format and Content
- Forms
- Filing and FDA Review Process
- Other IND Formats
- IND Maintenance
- Case Scenarios
Caring for and Feeding Your IND
IND Maintenance

- IND Amendments (Protocol, Information, Safety, Annual Reports)
- Notes on Multi-center Studies
- Cover Letters
- Financial Disclosure
- Ending an IND
**IND Maintenance**

11. This submission contains the following *(Select all that apply)*

- Initial Investigational New Drug Application (IND)
- Request for Reactivation or Reinstatement
- Development Safety Update Report (DSUR)
- Response to Clinical Hold
- Annual Report
- Other *(Specify):*

<table>
<thead>
<tr>
<th>Protocol Amendment(s)</th>
<th>Information Amendment(s)</th>
<th>Request for</th>
<th>IND Safety Report(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Protocol</td>
<td>Chemistry/Microbiology</td>
<td>Meeting</td>
<td>Initial Written Report</td>
</tr>
<tr>
<td>Change in Protocol</td>
<td>Pharmacology/Toxicology</td>
<td>Proprietary Name Review</td>
<td>Follow-up to a Written Report</td>
</tr>
<tr>
<td>New Investigator</td>
<td>Clinical</td>
<td>Special Protocol Assessment</td>
<td></td>
</tr>
<tr>
<td>PMR/PMC Protocol</td>
<td>Clinical Pharmacology</td>
<td>Formal Dispute Resolution</td>
<td></td>
</tr>
</tbody>
</table>

**FDA Form 1571: Box 11**

Maintenance of an IND includes any and all of the above types of submissions.
Four Kinds. . .

1. New Protocol
2. Change in Protocol
3. New Investigator
4. PMR/PMC Protocol

From Form 1571: Box 11
Protocol Amendments

New Protocols & Protocol Changes

- Can be submitted to an existing IND
- Must include a brief summary of the differences between new/revised protocol and previous protocol(s)
- No 30 day clock with FDA submission—Must have IRB approval before beginning
- You are **strongly** encouraged to check with your FDA project manager
- FDA & IRB submissions may occur in any order
- Should send IRB approval letters to FDA
Protocol Amendments

Change in Protocol (cont.)

What changes must be reported (regulation):

Phase 1: changes that significantly affect the safety of subjects

Phase 2 or 3: changes that significantly affect the safety of subjects, the scope of the investigation, or the scientific quality of the study
Change in Protocol (cont.)

What changes should be reported *(best practice)*:

- Phase 1: all changes
- Phase 2 or 3: all changes
Protocol Amendments

- **EXCEPTION:** a change intended to eliminate an apparent immediate hazard to subjects may be implemented immediately provided subsequent FDA and IRB notification.
Protocol Amendments

New Investigator

- Relevant for multi-center studies
- FDA must be notified of the new principal investigator (i.e. a site opening) within 30 days of them enrolling their first subject
- Sponsor must collect and submit the 1572 and CV of the PI from each site to the FDA
- Sponsor must collect the IRB approval letter from each site prior to shipping drug and should submit to FDA
Information Amendments

Five Kinds...
Select review discipline to which submission applies.

1. Chemistry/Micro
2. Pharm/Tox
3. Clinical
4. Statistics
5. Clinical Pharmacology

From Form 1571: Box 11

Information Amendment(s)
- Chemistry/Microbiology
- Pharmacology/Toxicology
- Clinical
- Statistics
- Clinical Pharmacology
Information Amendments

- Generally comprised of new technical information
- Statement identifying the nature and purpose of the amendment
- Note: Discontinuation of a clinical study can be submitted as an Information Amendment under “clinical”
- Submit information amendments as needed but, if possible, not more than every 30 days.
IND Safety Reports

Two Kinds.

1. Initial Written Report
2. Follow-Up to a Written Report

From Form 1571: Box 11

IND Safety Report(s)
- Initial Written Report
- Follow-up to a Written Report
IND Safety Reports

- Serious and Unexpected Adverse Events associated with the use of the drug must be reported ‘quickly’

- Further, any findings from animal studies that suggest a significant risk for human subjects must also be reported ‘quickly’

- The sponsor-investigator must notify the FDA and all participating investigators
IND Safety Reports

Serious Adverse Drug Experience: Any adverse drug experience occurring at any dose that results in any of the following outcomes:

- death
- a life-threatening adverse drug experience,
- inpatient hospitalization or prolongation of existing hospitalization,
- a persistent or significant disability/incapacity
- or a congenital anomaly/birth defect.
Unexpected Adverse Drug Experience:

• Any event in which the specificity or severity of which is not consistent with the current investigator brochure (IB) or package insert;

• or, if an IB is not required or available, the specificity or severity of which is not consistent with the risk information described in the general investigational plan or elsewhere in the application

Note: ‘expected’ does not include events anticipated based on pharmacological properties (i.e. not theoretical expectedness)
<table>
<thead>
<tr>
<th>Type of SAE</th>
<th>FDA Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unexpected fatal or life-threatening adverse drug experience</td>
<td>7 calendar days</td>
</tr>
<tr>
<td>Serious and unexpected adverse drug experience</td>
<td>15 calendar days</td>
</tr>
<tr>
<td>New animal findings that suggest significant risk to human subjects</td>
<td>15 calendar days</td>
</tr>
<tr>
<td>Follow-up reports</td>
<td>As relevant information is available</td>
</tr>
</tbody>
</table>
Use the Correct MedWatch Form

FDA Form 3500 (Voluntary MedWatch):
• For use by healthcare professionals, consumers, and patients. Submit by mail, fax or online

FDA Form 3500A (Mandatory MedWatch):
• For use by IND reporters, manufacturers, distributors, importers, user facilities personnel
IND Safety Reports

- May submit via FDA Form 3500A or in a narrative format (foreign events may use CIOMS I form)

- In the report, identify all safety reports previously filed to the IND for similar adverse experience, and analyze the significance of the adverse experience in light of the previous, similar reports.
Case Studies. . .(if time allows)

IND Safety Reports and IND Maintenance
Annual Reports

Due within 60 days of the anniversary of your IND (Effective Date)

From Form 1571: Box 11

☐ Response to Clinical Hold
☐ Annual Report
☐ Other (Specify): ________

Templates can be found at our website
Annual Reports - Content

1. Individual Study Information
2. Summary Information (Safety)
3. General Investigational Plan
4. Investigator Brochure
5. Protocol Modifications
6. Foreign Marketing Developments
7. Outstanding Business
11. This submission contains the following (Select all that apply)

- Initial Investigational New Drug Application (IND)
- Response to Clinical Hold
- Response To FDA Request For Information
- Request For Reactivation Or Reinstatement
- Annual Report
- General Correspondence
- Development Safety Update Report (DSUR)
- Other (Specify):

Protocol Amendment(s)
- New Protocol
- Change in Protocol
- New Investigator
- PMR/PMC Protocol

Information Amendment(s)
- Chemistry/Microbiology
- Pharmacology/Toxicology
- Clinical
- Statistics
- Clinical Pharmacology

Request for
- Meeting
- Proprietary Name Review
- Special Protocol Assessment
- Formal Dispute Resolution

IND Safety Report(s)
- Initial Written Report
- Follow-up to a Written Report

FDA Form 1571: Box 11

Submissions should be filed as needed but, if possible, not more than every 30 days.
IND Maintenance

- IND Amendments (Protocol, Information, Safety, Annual Reports)

- Notes on Multi-center Studies

- Cover Letters

- Financial Disclosure

- Ending an IND
Multi-Center Studies

As a sponsor you . . .

- **Must obtain 1572 & CV of PI from each site**
  - Must submit to the FDA within 30 days of the site’s first enrollment

- **Must obtain the IRB approval letter from each site**
  - Should submit to the FDA

- **Must monitor your study at each site**
  - In person, by mail or electronically
Multi-Center Studies

As a sponsor you. . .

- Must send IND safety reports to each site (in addition to the FDA)
  - Each PI must also submit to their IRB

- Should request information early for annual reporting requirements
  - This makes life easier for you

Always remember, you have ultimate responsibility!
IND Maintenance

- IND Amendments (Protocol, Information, Safety, Annual Reports)
- Notes on Multi-center Studies
- Cover Letters
- Financial Disclosure
- Ending an IND
Cover Letters

• Ideally dated the date of submission
• Should summarize the content of your submission
• May ask questions or ask for FDA comment on items
• Important to list an alternate contact person
IND Maintenance

- IND Amendments (Protocol, Information, Safety, Annual Reports)
- Notes on Multi-center Studies
- Cover Letters
- Financial Disclosure
- Ending an IND
Financial Disclosure Forms

21 CFR Part 54

• Applies only to studies that will be used in support of a marketing application (NDA or BLA) or
• Any study in which a single investigator makes a significant contribution to the demonstration of safety
Therefore, in general...

- **Phase I Studies** – Not Applicable
  - Unless they are critical for demonstrating efficacy (in a marketing application)

- **Sponsor-Investigator Studies** – Not Applicable

In any case, they are never submitted to INDs (only with marketing applications)
IND Maintenance

- IND Amendments (Protocol, Information, Safety, Annual Reports)
- Notes on Multi-center Studies
- Cover Letters
- Financial Disclosure
- Ending an IND
The End of an IND

• Withdrawal - Initiated by the sponsor
  – If withdrawn for safety reason, IRB must be notified

• Inactive Status – Initiate by FDA or sponsor
  – FDA may inactivate IND if no subjects are entered into clinical studies in 2 years or an investigation remains on clinical hold for >1 year (or sponsor can request this action)
  – A sponsor is not required to submit an annual report
  – An inactive IND can be reactivated via a protocol amendment
  – INDs inactive for > 5 years may be terminated by the FDA

• Termination – Initiated by the FDA
  – based on safety issues, deficiencies in the IND or in the conduct of an investigation
  – sponsors usually have a chance to respond
Questions???